StockWatch
·
Filing
Q2

Windlas Biotech Ltd

WINDLASFY2606 Nov 2025
Revenue+5.9%
Net Profit+0.8%
OPM12.84%

P&L

Quarterly Consolidated

Revenue
+5.9%222.40
Expenditure
+5.4%202.46
Net Profit
+0.8%17.80
NPM 7.87%-4.0%EPS ₹8.48+0.6%

vs Q1 FY26

Windlas Biotech Ltd Announces Q2 and H1 Results for FY2025: Revenue from Operations at INR 2,223.98 Million

06 Nov 2025 · 6 Nov 2025, 06:43 pm

Summary

The Board of Directors of Windlas Biotech Ltd approved the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year ended September 30, 2025. The company's revenue from operations stands at INR 2,223.98 Million.

Key Highlights

  1. 1

    Q2 and H1 results for FY2025 announced

  2. 2

    Revenue from Operations at INR 2,223.98 Million

  3. 3

    Board of Directors approved the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year ended September 30, 2025

Informational and educational content only. Not investment advice.